Low-dose digoxin cuts heart-failure hospitalizations 25% — SkimNews
SkimNews Take
A centuries-old, sub-10-cent drug still cutting hospitalizations by 25% points to a structural blind spot: off-patent therapies rarely attract the trial funding that newer alternatives command.
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- UMCG cardiologists Dirk Jan van Veldhuisen, Kevin Damman, and Peter van der Meer led three studies — published in Nature Medicine and JAMA and presented at the ESC Heart Failure Congress in Barcelona — showing low-dose digoxin cuts heart-failure hospitalizations by 25%.
- The 1,000-patient Dutch trial across 43 centers ran for an average of three years with digoxin added to the standard 'Fantastic Four' heart-failure regimen; cardiovascular deaths fell 19% but that single result didn't reach statistical significance on its own.
- A meta-analysis combining the new trial with two earlier studies produced statistically significant benefits across the larger patient pool, strengthening the case for digoxin as a potential fifth standard treatment.
- Among roughly 600 follow-up participants, those who stopped taking digoxin saw significantly more health problems in the first six weeks after discontinuation — 14 of 288 patients were hospitalized or died.
- Digoxin costs less than 10 cents per day versus several euros for newer heart-failure drugs, yet is currently prescribed to only about 15% of heart-failure patients despite centuries of medical use.
- The Hartstichting funded the 3-million-euro study through ZonMw's Good Use of Medicines program, filling a gap left by commercial funders reluctant to back research on older, inexpensive medications.
Why it matters: More than 500,000 people in the Netherlands have heart failure, with that figure expected to grow. If guidelines shift, that patient pool — and millions worldwide — could gain access to a treatment costing under 10 cents a day versus several euros for newer alternatives, dramatically lowering drug costs for healthcare systems while expanding prescribing beyond the current 15% of patients who receive digoxin.
Ask SkimNews
